Oncology & Cancer

Neoadjuvant PD-1 blockade seems effective in glioblastoma

(HealthDay)—Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in Nature ...

Oncology & Cancer

Study links genetic mutation and melanoma progression

Dartmouth researchers have found that the genetic mutation BRAFV600E, frequently found in metastatic melanoma, not only secretes a protein that promotes the growth of melanoma tumor cells, but can also modify the network ...

Oncology & Cancer

Scientists detect new ovarian cancer target

Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium ...

Oncology & Cancer

A new mechanism of drug resistance discovered for breast cancer

Scientists from Università Cattolica in Rome, together with colleagues from the IIGM Foundation (part of Candiolo Institute at Turin), have discovered a new drug-resistance mechanism in breast cancer that leads to the formation ...

Oncology & Cancer

Study identifies new therapeutic target for tumor treatment

Northwestern Medicine scientists have identified a new therapeutic target for tumors and developed a compound which slowed tumor growth and bolsters immune responses in mice, according to research published in Science Advances.

Oncology & Cancer

Improving cancer immunotherapy by prolonging T-cell survival

In the past decade, immunotherapy has emerged as the fourth pillar of cancer treatment, joining surgery, radiotherapy and chemotherapy. It is an approved treatment for 15 cancers, including melanoma and some types of lymphomas ...

page 27 from 40